CAN backs Laboratorios Ojer Pharma with €500,000
Corporación Caja Navarra (CAN), the private equity arm of Caja Navarra, has invested €500,000 in biotech company Laboratorios Ojer Pharma in return for a 11.22% in the business.
CAN's investment is part of a wider Navarre Investment Plan that will invest €20m in innovative and strategic entrepreneurial projects in the Navarre region.
Company
Launched in 2005 and based in Zizur Mayor, Laboratorios Ojer Pharma is a spin off from the University of Navarre. It currently has four products, which are in different phases of development - two of which are set to be authorised for commercialisation in the upcoming months. Other shareholders in the company are the Fundacion Universidad de Navarra and Clave Mayor through its funds Ronda Vida and Real de Vellon.
People
Javier Martinez Escudero represented CAN on the transaction. Carlos Gonzalez Ojer is the director of Laboratorios Ojer Pharma.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








